Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with AML transformed from MDS previously treated with azacitidine monotherapy.

Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease ...

IDH1 mutations in MDS are crucial for guiding therapy decisions, offering one of the few targetable mutations in this disease ...

Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients On the basis of a nationwide MPN ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

– Decision Based on Review of the Comprehensive Safety Data from Each Trial – With today’s decision from the FDA, enrollment in the U.S. can resume for the studies investigating magrolimab in ...

—In a recent study, investigators in Spain sought to discover which gene mutations were responsible for the transformation of myelodysplastic syndrome (MDS) to secondary acute myeloid leukemia (sAML).

The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.

—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...